***生物化学制药厂易地重建为***华盛生物制药有限公司工程环境影响报告书***市环境保护科学研究所所长：项目负责人：工程师国环评岗字报告书编写：工程师高级工程师助理工程师审核：高级工程师总工程师前言***生物化学制药厂始建于1958年。现生产制银灵、氨肽素、多酶片等30多个品种，销往全国各地。特别是氨肽素片为国内首创，曾荣获商业部重大科技成果奖。生物制药因技术含量高、附加值高、临床用途广泛，是目前国内外制药行业竞争发展的方向。我国加入WTO后，此类药品将具有更广阔的发展空间。而***生物化学制药厂因2号干线改造工程占用厂区2/3的面积，导致厂房、设备、生产环境与同行业相比差距越来越大。特别是国家药品监督管理局强制推行制药企业“GMP”认证(药品生产质量管理规定)，限定在2003年底之前完成，否则将取消药厂的药品生产资格。而生物药厂目前的地理环境、厂房、设备等现有条件不符合“GMP”认证要求，必须易地重建才能达标。否则，***生物药厂到2003年底就要停产。根据中华人民共和国国务院第253号令《建设项目环境保护管理条例》，受建设单位委托，***市环境保护科学研究所承担了***生物化学制药厂易地重建为***华盛生物制药有限公司工程的环境影响评价工作。本环境影响评价得到了***生物化学制药厂和振安区环保局的大力协助，在此表示感谢。目录第一章总则···············································································11.1编制目的·······································································11.2编制依据·······································································11.3评价标准·······································································21.4控制污染与保护环境目标··················································21.5评价重点·······································································31.6评价工作等级·································································31.7评价范围·······································································31.8评价工作程序·································································4第二章建设项目概况···································································62.1建设项目名称、位置及建设性质·········································62.2建设规模、占地及平面布置···············································62.3建设项目投资及资金来源··················································72.4年销售收入、税金及附加估算············································82.5项目实施进度规划···························································82.6主要经济技术指标················································...
